Physician profile
Eric Chen
NPI 1508482472
$4,194.42
in general payments reported to CMS, 2019-2025
21 companies · $2,883 in 2025
The $2,883 reported for 2025 was more than what 92% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $121 · 2024: $1,191 · 2025: $2,883.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,071 · Education: $2.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,071.17 |
| Education | $2.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $588.34 | 2024-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $481.12 | 2024-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $439.45 | 2024-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Corium, LLC | $416.09 | 2024-2025 | Azstarys |
| Janssen Pharmaceuticals, INC | $388.86 | 2024-2025 | Spravato, Invega Sustenna, Invega |
| E.R. Squibb & Sons, L.L.C. | $278.31 | 2024-2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $265.43 | 2024-2025 | Trintellix |
| Lundbeck LLC | $239.02 | 2024-2025 | Rexulti |
| Abbvie INC. | $232.37 | 2024-2025 | |
| Alkermes, INC. | $222.57 | 2025 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $181.93 | 2024-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Supernus Pharmaceuticals, INC. | $124.99 | 2024 | Qelbree |
| Stryker Corporation | $121.11 | 2021 | |
| Axsome Therapeutics, INC. | $48.62 | 2024-2025 | Auvelity |
| Neos Therapeutics, Lp | $40.13 | 2025 | Adzenys Xr-Odt |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $29.24 | 2025 | Fanapt |
| Bausch Health US, LLC | $23.05 | 2025 | Aplenzin, Wellbutrin |
| Vertical Pharmaceuticals, LLC | $20.28 | 2025 | Relexxii |
| Tris Pharma INC | $18.54 | 2024 | Dyanavel Xr |
| Idorsia Pharmaceuticals US INC | $18.44 | 2024 | Quviviq |
| Luye Pharma (USA) Ltd. | $16.53 | 2025 | Erzofri Extended-Release |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.